zoledronic acid indications/contra

Stem definitionDrug idCAS RN
calcium metabolism regulator, pharmaceutical aid 2868 118072-93-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • zoledronic acid
  • zoledronate
  • zoledronic acid monohydrate
  • zometa
  • zoledronic acid hydrate
a potent inhibitor of bone resorption; structure given in first source
  • Molecular weight: 272.09
  • Formula: C5H10N2O7P2
  • CLOGP: -3.07
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 5
  • TPSA: 153.11
  • ALOGS: -1.92
  • ROTB: 4

Drug dosage:

DoseUnitRoute
4 mg P

Approvals:

DateAgencyCompanyOrphan
March 20, 2001 EMA
Aug. 20, 2001 FDA NOVARTIS

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Osteonecrosis 25898.83 33.69 4845 15386 6054 3359574
Osteonecrosis of jaw 23949.54 33.69 4516 15715 5980 3359648
Bone disorder 8343.92 33.69 1635 18596 2654 3362974
Tooth extraction 8339.78 33.69 1572 18659 1791 3363837
Pain in jaw 5756.34 33.69 1278 18953 4780 3360848
Osteomyelitis 5288.33 33.69 1154 19077 3886 3361742
Exposed bone in jaw 5064.11 33.69 872 19359 236 3365392
Pain 4045.39 33.69 1709 18522 69848 3295780
Impaired healing 3739.48 33.69 926 19305 6022 3359606
Primary sequestrum 2748.10 33.69 472 19759 113 3365515
Bone pain 2526.29 33.69 730 19501 9031 3356597
Purulent discharge 2325.83 33.69 461 19770 783 3364845
Debridement 2053.34 33.69 370 19861 231 3365397
Malignant neoplasm progression 2048.59 33.69 718 19513 17075 3348553
Gingivitis 2005.25 33.69 434 19797 1358 3364270
Jaw disorder 1941.22 33.69 414 19817 1181 3364447
Pyrexia 1936.62 33.69 1079 19152 80036 3285592
Arthralgia 1927.21 33.69 978 19253 59883 3305745
Bone lesion 1889.17 33.69 371 19860 582 3365046
Sequestrectomy 1876.59 33.69 327 19904 112 3365516
Swelling 1839.65 33.69 675 19556 18369 3347259
Metastases to bone 1819.91 33.69 443 19788 2618 3363010
Toothache 1764.61 33.69 426 19805 2417 3363211
Fistula 1629.55 33.69 381 19850 1837 3363791
Osteitis 1552.87 33.69 312 19919 586 3365042
Myalgia 1531.01 33.69 685 19546 31390 3334238
Hypocalcaemia 1470.80 33.69 428 19803 5393 3360235
Bone debridement 1415.18 33.69 243 19988 56 3365572
Tooth disorder 1393.61 33.69 390 19841 4224 3361404
Influenza like illness 1381.42 33.69 511 19720 14176 3351452

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC M05BA08 MUSCULO-SKELETAL SYSTEM
DRUGS FOR TREATMENT OF BONE DISEASES
DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
Bisphosphonates
ATC M05BB08 MUSCULO-SKELETAL SYSTEM
DRUGS FOR TREATMENT OF BONE DISEASES
DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
Bisphosphonates, combinations
CHEBI has role CHEBI:50646 bone density conservation agent
MeSH PA D050071 Bone Density Conservation Agents

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Osteitis deformans indication 2089002 DOID:5408
Humoral hypercalcemia of malignancy indication 47709007
Osteoporosis indication 64859006 DOID:11476
Postmenopausal osteoporosis indication 102447009
Prevention of Glucocorticoid-Induced Osteoporosis indication
Glucocorticoid Induced Osteoporosis indication
Osteolytic Lesions of Multiple Myeloma indication
Hypogonadal Osteoporosis in Males indication
Bone Metastases of Solid Tumors indication
Intracranial hemorrhage contraindication 1386000
Anuria contraindication 2472002 DOID:2983
Hypophosphatemia contraindication 4996001
Hypocalcemia contraindication 5291005
Bone pain contraindication 12584003
Hyperkalemia contraindication 14140009
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Hypoparathyroidism contraindication 36976004 DOID:11199
Hypernatremia contraindication 39355002
Chronic heart failure contraindication 48447003
Joint pain contraindication 57676002
Acute nephropathy contraindication 58574008
Pulmonary congestion contraindication 67599009
Muscle pain contraindication 68962001
Fracture of femur contraindication 71620000
Oliguria contraindication 83128009
Hyponatremia contraindication 89627008
Small intestine excision contraindication 107938000
Hypomagnesemia contraindication 190855004
Impaired renal function disorder contraindication 197663003
Tooth disorder contraindication 234947003 DOID:1091
Fragile capillaries contraindication 248726001
Pregnancy, function contraindication 289908002
Breastfeeding (mother) contraindication 413712001
Aseptic necrosis of bone of jaw contraindication 441809006
Severe dehydration contraindication 450316000
Invasive Dental Procedure contraindication
Thyroid Surgery contraindication
Malabsorption States contraindication
Drug-induced osteoporosis off-label use 14651005

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 1.38 acidic
pKa2 5.45 acidic
pKa3 6.59 acidic
pKa4 10.35 acidic
pKa5 11.04 acidic
pKa6 5.92 Basic

Orange Book patent data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 5MG BASE/100ML RECLAST NOVARTIS N021817 April 16, 2007 RX INJECTABLE IV (INFUSION) 8052987 Oct. 27, 2023 TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
EQ 4MG BASE/100ML ZOMETA NOVARTIS N021223 June 17, 2011 RX INJECTABLE IV (INFUSION) 8324189 May 29, 2025 BONE METASTASES
EQ 4MG BASE/100ML ZOMETA NOVARTIS N021223 June 17, 2011 RX INJECTABLE IV (INFUSION) 8324189 May 29, 2025 HYPERCALCEMIA OF MALIGNANCY
EQ 4MG BASE/100ML ZOMETA NOVARTIS N021223 June 17, 2011 RX INJECTABLE IV (INFUSION) 8324189 May 29, 2025 MULTIPLE MYELOMA
EQ 4MG BASE/5ML ZOMETA NOVARTIS N021223 March 7, 2003 RX INJECTABLE IV (INFUSION) 8324189 May 29, 2025 BONE METASTASES
EQ 4MG BASE/5ML ZOMETA NOVARTIS N021223 March 7, 2003 RX INJECTABLE IV (INFUSION) 8324189 May 29, 2025 HYPERCALCEMIA OF MALIGNANCY
EQ 4MG BASE/5ML ZOMETA NOVARTIS N021223 March 7, 2003 RX INJECTABLE IV (INFUSION) 8324189 May 29, 2025 MULTIPLE MYELOMA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Farnesyl pyrophosphate synthase Enzyme INHIBITOR Ki 10.15 CHEMBL CHEMBL
72 kDa type IV collagenase Enzyme IC50 5.15 CHEMBL
Neutrophil collagenase Enzyme IC50 4.75 CHEMBL
Geranylgeranyl pyrophosphate synthase Enzyme Ki 5.57 CHEMBL
Carbonic anhydrase 2 Enzyme IC50 7.21 CHEMBL
Carbonic anhydrase 14 Enzyme IC50 7.04 CHEMBL
Carbonic anhydrase 12 Enzyme IC50 6.50 CHEMBL
Carbonic anhydrase 9 Enzyme IC50 5.27 CHEMBL
Matrix metalloproteinase-14 Enzyme IC50 4.90 CHEMBL
Matrix metalloproteinase-9 Enzyme IC50 4.28 CHEMBL
Geranylgeranyl pyrophosphate synthase Enzyme Ki 6.59 CHEMBL
Farnesyl pyrophosphate synthase Enzyme Ki 7.96 CHEMBL
Farnesyl diphosphate synthase Enzyme IC50 5.96 CHEMBL
Farnesyl pyrophosphate synthase Unclassified INHIBITOR IC50 6.30 IUPHAR

External reference:

scroll-->
IDSource
DB00399 DRUGBANK_ID
3177 IUPHAR_LIGAND_ID
4021276 VUID
N0000179387 NUI
C0257685 UMLSCUI
D01968 KEGG_DRUG
6XC1PAD3KF UNII
165800-06-6 SECONDARY_CAS_RN
CHEMBL924 ChEMBL_ID
68740 PUBCHEM_CID
N0000179387 NDFRT
N0000148713 NDFRT
008997 NDDF
199263 MMSL
d04708 MMSL
15839 MMSL
77655 RXNORM
4021276 VANDF
134600006 SNOMEDCT_US
395926009 SNOMEDCT_US
CHEBI:46557 CHEBI
C088658 MESH_SUPPLEMENTAL_RECORD_UI
ZOL PDB_CHEM_ID

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Zometa HUMAN PRESCRIPTION DRUG LABEL 1 0078-0387 INJECTION, SOLUTION, CONCENTRATE 4 mg INTRAVENOUS NDA 16 sections
Reclast HUMAN PRESCRIPTION DRUG LABEL 1 0078-0435 INJECTION, SOLUTION 5 mg INTRAVENOUS NDA 17 sections
Zometa HUMAN PRESCRIPTION DRUG LABEL 1 0078-0590 INJECTION, SOLUTION, CONCENTRATE 4 mg INTRAVENOUS NDA 16 sections
Zoledronic Acid HUMAN PRESCRIPTION DRUG LABEL 1 0143-9642 INJECTION, SOLUTION, CONCENTRATE 4 mg INTRAVENOUS ANDA 17 sections
ZOLEDRONIC ACID HUMAN PRESCRIPTION DRUG LABEL 1 0409-4215 INJECTION, SOLUTION, CONCENTRATE 4 mg INTRAVENOUS ANDA 17 sections
ZOLEDRONIC ACID HUMAN PRESCRIPTION DRUG LABEL 1 0409-4228 INJECTION, SOLUTION 5 mg INTRAVENOUS ANDA 17 sections
Zoledronic Acid HUMAN PRESCRIPTION DRUG LABEL 1 0409-4229 INJECTION, SOLUTION 4 mg INTRAVENOUS NDA 17 sections
Zoledronic acid HUMAN PRESCRIPTION DRUG LABEL 1 16729-242 INJECTION 4 mg INTRAVENOUS ANDA 17 sections
Zoledronic Acid HUMAN PRESCRIPTION DRUG LABEL 1 17478-324 SOLUTION 5 mg INTRAVENOUS ANDA 17 sections
Zoledronic Acid HUMAN PRESCRIPTION DRUG LABEL 1 17478-327 INJECTION, SOLUTION, CONCENTRATE 4 mg INTRAVENOUS ANDA 16 sections
Zoledronic acid HUMAN PRESCRIPTION DRUG LABEL 1 23155-170 INJECTION, SOLUTION, CONCENTRATE 4 mg INTRAVENOUS ANDA 17 sections
Zoledronic acid HUMAN PRESCRIPTION DRUG LABEL 1 23155-186 INJECTION, SOLUTION 5 mg INTRAVENOUS ANDA 17 sections
Zoledronic acid HUMAN PRESCRIPTION DRUG LABEL 1 23155-525 INJECTION, SOLUTION 5 mg INTRAVENOUS ANDA 18 sections
Zoledronic Acid HUMAN PRESCRIPTION DRUG LABEL 1 25021-801 INJECTION, SOLUTION, CONCENTRATE 0.80 mg INTRAVENOUS ANDA 17 sections
zoledronic acid HUMAN PRESCRIPTION DRUG LABEL 1 25021-826 INJECTION, SOLUTION 0.04 mg INTRAVENOUS NDA 16 sections
zoledronic acid HUMAN PRESCRIPTION DRUG LABEL 1 25021-830 INJECTION, SOLUTION 0.05 mg INTRAVENOUS ANDA 17 sections
Zoledronic Acid HUMAN PRESCRIPTION DRUG LABEL 1 42023-151 INJECTION, SOLUTION, CONCENTRATE 4 mg INTRAVENOUS ANDA 17 sections
Zoledronic Acid HUMAN PRESCRIPTION DRUG LABEL 1 42023-163 INJECTION, SOLUTION 5 mg INTRAVENOUS ANDA 17 sections
Zoledronic Acid HUMAN PRESCRIPTION DRUG LABEL 1 42023-167 INJECTION, SOLUTION, CONCENTRATE 4 mg INTRAVENOUS ANDA 17 sections
Zoledronic Acid HUMAN PRESCRIPTION DRUG LABEL 1 43598-330 INJECTION, SOLUTION, CONCENTRATE 4 mg INTRAVENOUS ANDA 16 sections
Zoledronic Acid HUMAN PRESCRIPTION DRUG LABEL 1 43598-331 INJECTION, SOLUTION 5 mg INTRAVENOUS ANDA 19 sections
Zoledronic Acid HUMAN PRESCRIPTION DRUG LABEL 1 45963-440 INJECTION, SOLUTION, CONCENTRATE 4 mg INTRAVENOUS ANDA 16 sections
Zoledronic Acid HUMAN PRESCRIPTION DRUG LABEL 1 51991-064 INJECTION 5 mg INTRAVENOUS ANDA 17 sections
Zoledronic Acid HUMAN PRESCRIPTION DRUG LABEL 1 51991-065 INJECTION, SOLUTION, CONCENTRATE 4 mg INTRAVENOUS ANDA 16 sections
Zoledronic Acid HUMAN PRESCRIPTION DRUG LABEL 1 55111-685 INJECTION, SOLUTION, CONCENTRATE 4 mg INTRAVENOUS ANDA 16 sections
Zoledronic Acid HUMAN PRESCRIPTION DRUG LABEL 1 55111-688 INJECTION, SOLUTION 5 mg INTRAVENOUS ANDA 18 sections
Zoledronic Acid HUMAN PRESCRIPTION DRUG LABEL 1 55150-266 INJECTION, SOLUTION, CONCENTRATE 4 mg INTRAVENOUS ANDA 16 sections
Zoledronic Acid HUMAN PRESCRIPTION DRUG LABEL 1 55150-283 INJECTION, SOLUTION 5 mg INTRAVENOUS ANDA 17 sections
Zoledronic Acid HUMAN PRESCRIPTION DRUG LABEL 1 60505-6110 INJECTION, SOLUTION, CONCENTRATE 4 mg INTRAVENOUS ANDA 16 sections
Zoledronic Acid HUMAN PRESCRIPTION DRUG LABEL 1 63323-961 INJECTION 4 mg INTRAVENOUS ANDA 17 sections